

NEWSFLASH



CerebroVascular Disease-Cognition phase-2 trial in non-lacunar ischaemic stroke with cerebral small vessel disease

We're pleased to share that the study has now received IRAS approval and ISCTRN registration. We are currently circulating LIPs to participating sites.

We welcome interest from any additional sites who would like to join – please contact us if you would like to get involved: CVD-Cog@nottingham.ac.uk.



Our study website is now live, please visit for more information on the study: <https://stroke.nottingham.ac.uk/cvd-cog/>

Trial Summary

PURPOSE: The purpose of CVD-COG is to investigate whether isosorbide mononitrate and/or cilostazol are effective in treating cSVD in patients who have had non-lacunar ischaemic stroke.

PARTICIPANTS: 400 participants will be recruited from 25 UK sites. Participants must be 7 days from diagnosis with a non-lacunar ischaemic stroke or TIA.

INTERVENTION: Participants not taking an oral anti-coagulant will be randomly assigned to one of four treatment groups: Cilostazol only; isosorbide mononitrate only; both cilostazol and isosorbide mononitrate; or neither cilostazol nor isosorbide mononitrate.

Participants on an oral anti-coagulant will be randomised to isosorbide mononitrate or no isosorbide mononitrate.

FOLLOW UP: Participants will be treated and followed for 6 months. The trial is funded for 3 years by Alzheimer's Society.

Follow our progress on **X** @CVDcog

If you have any questions please get in touch:



CVD-Cog@nottingham.ac.uk